Spark Therapeutics (NASDAQ:ONCE) had its price objective raised by equities researchers at BMO Capital Markets from $46.00 to $114.50 in a report released on Tuesday, February 26th, The Fly reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 1.33% from the company’s previous close.
Several other research firms also recently weighed in on ONCE. SunTrust Banks downgraded Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 25th. Raymond James cut Spark Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday, February 25th. ValuEngine raised Spark Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 25th. William Blair initiated coverage on Spark Therapeutics in a research report on Tuesday, February 26th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $80.00 price objective on shares of Spark Therapeutics in a research report on Sunday, February 17th. Seventeen investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $77.26.
Shares of ONCE stock traded down $0.27 during trading hours on Tuesday, reaching $113.00. 4,039,370 shares of the company’s stock were exchanged, compared to its average volume of 4,273,852. The company has a market cap of $4.29 billion, a price-to-earnings ratio of -53.55 and a beta of 2.59. Spark Therapeutics has a 1 year low of $34.53 and a 1 year high of $114.20. The company has a current ratio of 9.10, a quick ratio of 8.68 and a debt-to-equity ratio of 0.09.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, February 19th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.89). Spark Therapeutics had a negative return on equity of 14.94% and a negative net margin of 121.78%. The business had revenue of $13.15 million for the quarter, compared to analysts’ expectations of $26.76 million. During the same period last year, the company posted ($1.63) earnings per share. The business’s quarterly revenue was up 47.9% on a year-over-year basis. On average, equities analysts forecast that Spark Therapeutics will post -4.52 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of the business. SG Americas Securities LLC boosted its stake in Spark Therapeutics by 7.0% in the fourth quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock valued at $188,000 after acquiring an additional 313 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Spark Therapeutics by 16.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after buying an additional 485 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Spark Therapeutics by 3.2% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,696 shares of the biotechnology company’s stock worth $693,000 after buying an additional 546 shares during the period. Mackay Shields LLC boosted its position in shares of Spark Therapeutics by 5.4% during the fourth quarter. Mackay Shields LLC now owns 12,322 shares of the biotechnology company’s stock worth $482,000 after buying an additional 633 shares during the period. Finally, Pearl River Capital LLC acquired a new position in shares of Spark Therapeutics during the fourth quarter worth approximately $31,000.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Further Reading: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.